Letters to the Editor
- Aust Prescr 1997;20:83-6
- 1 October 1997
- DOI: 10.18773/austprescr.1997.077
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – I refer to the previous correspondence regarding the confusion over the use of Coumadin and Marevan ('Letters' Aust Prescr 1997;20:33).
If no immediate solution exists, all new patients should be commenced on one dominant brand, and the other used only for continuation of treatment. This should progressively eliminate confusion, so that in 5 years, remaining patients could be converted, at smaller risk and inconvenience.
John D. Egan